This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zorrilla, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zorrilla, C. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2007, p. 2208-2210, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.00871-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Clinical Response and Tolerability to and Safety of Saquinavir with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Mothers and Their Infants{triangledown} ,{dagger}

Carmen D. Zorrilla,1* Russell Van Dyke,2 Arlene Bardeguez,3 Edward P. Acosta,4 Betsy Smith,5 Michael D. Hughes,6 Sharon Huang,6 D. Heather Watts,7 Barbara Heckman,8 Eleanor Jiménez,9 George McSherry,3 Lynne Mofenson,8 and the Pediatric AIDS Clinical Trials Group 386 Protocol Team

University of Puerto Rico School of Medicine, San Juan, Puerto Rico,1 Tulane University Medical School, New Orleans, Louisiana,2 New Jersey Medical School, Newark, New Jersey,3 University of Alabama at Birmingham, Birmingham, Alabama,4 Division of AIDS, NIAID, Bethesda, Maryland,5 Harvard School of Public Health, Boston, Massachusetts,6 Pediatric, Adolescent, and Maternal AIDS Branch, NICHD, Bethesda, Maryland,7 Frontier Science and Technology Research Foundation, Amherst, New York,8 San Juan City Hospital, San Juan, Puerto Rico9

Received 14 July 2006/ Returned for modification 1 September 2006/ Accepted 2 April 2007

Saquinavir boosted with low-dose ritonavir given with zidovudine and lamivudine was well tolerated by pregnant women and their infants. All mothers had <400 human immunodeficiency virus type 1 RNA copies/ml at delivery. Two had elevated liver transaminases and amylase. Seven infant adverse events were possibly treatment related (anemia, neutropenia, and hyperbilirubinemia).

* Corresponding author. Mailing address: Obstetrics and Gynecology Department, UPR School of Medicine, P.O. Box 365067, San Juan, Puerto Rico 00936-5067. Phone: (787) 771-4740. Fax: (787) 771-4739. E-mail: czorrilla{at}rcm.upr.edu

{triangledown} Published ahead of print on 9 April 2007.

{dagger} This is a PACTG 386 study.

Antimicrobial Agents and Chemotherapy, June 2007, p. 2208-2210, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.00871-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»